Comunicati Stampa


Xeptagen findings published in the latest issue

Xeptagen findings published in the latest issue of Cancer Detection and Prevention may open a new gateway for the management of prostate cancer patients. The study provides the first evidence that circulating prostate specific antigens (PSA) may be detected complexed to IgM at significantly elevated levels in a much higher number of patients with prostate cancer compared to free PSA levels, therefore achieving the needed discrimination between benign prostatic hypertrophy and prostate cancer. Assessment of PSA-IgM levels in the free PSA grey zone (4 ng/mL - 10 ng/mL), where the outcome of biopsies is most equivocal and unpredictable, leads to a clear identification of cancer patients. Due to the limited overlapping of serum levels of PSA-IgM and PSA, the combined use of both biomarkers improves even further the accuracy of prostate cancer detection.